Research ArticleClinical Studies
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
LETIZIA GIANONCELLI, GIANLUCA SPITALERI, ANTONIO PASSARO, DAVIDE RADICE, CATERINA FUMAGALLI, ESTER DEL SIGNORE, VALERIA STATI, CHIARA MATILDE CATANIA, ELENA GUERINI-ROCCO, MASSIMO BARBERIS and FILIPPO DE MARINIS
Anticancer Research January 2020, 40 (1) 427-433; DOI: https://doi.org/10.21873/anticanres.13970
LETIZIA GIANONCELLI
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
GIANLUCA SPITALERI
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
ANTONIO PASSARO
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
DAVIDE RADICE
2Division of Epidemiology and Biostatistics European Institute of Oncology, IRCCS, Milan, Italy
CATERINA FUMAGALLI
3Division of Pathology & Laboratory Medicine, European Institute of Oncology, IRCCS, Milan, Italy
ESTER DEL SIGNORE
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
VALERIA STATI
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
CHIARA MATILDE CATANIA
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
ELENA GUERINI-ROCCO
3Division of Pathology & Laboratory Medicine, European Institute of Oncology, IRCCS, Milan, Italy
MASSIMO BARBERIS
3Division of Pathology & Laboratory Medicine, European Institute of Oncology, IRCCS, Milan, Italy
FILIPPO DE MARINIS
1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
In this issue
Anticancer Research
Vol. 40, Issue 1
January 2020
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
LETIZIA GIANONCELLI, GIANLUCA SPITALERI, ANTONIO PASSARO, DAVIDE RADICE, CATERINA FUMAGALLI, ESTER DEL SIGNORE, VALERIA STATI, CHIARA MATILDE CATANIA, ELENA GUERINI-ROCCO, MASSIMO BARBERIS, FILIPPO DE MARINIS
Anticancer Research Jan 2020, 40 (1) 427-433; DOI: 10.21873/anticanres.13970
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
LETIZIA GIANONCELLI, GIANLUCA SPITALERI, ANTONIO PASSARO, DAVIDE RADICE, CATERINA FUMAGALLI, ESTER DEL SIGNORE, VALERIA STATI, CHIARA MATILDE CATANIA, ELENA GUERINI-ROCCO, MASSIMO BARBERIS, FILIPPO DE MARINIS
Anticancer Research Jan 2020, 40 (1) 427-433; DOI: 10.21873/anticanres.13970
Jump to section
Related Articles
- No related articles found.
Cited By...
- TRAF6 modulates PD-L1 expression through YAP1-TFCP2 signaling in melanoma
- KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer
- Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group